 | • レポートコード：MRC2312MG07850 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、146ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥455,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥682,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場規模と予測を収録しています。・世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：売上、2018年-2023年、2024年-2029年 ・世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「モノクローナル抗体治療」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 発作性夜間ヘモグロビン尿症（PNH）用治療のグローバル主要企業は、Amoun Pharmaceuticals、 EIPICO、 Minapharm Pharmaceuticals、 Pharco Pharmaceuticals、 Alexion Pharmaceuticals、 Alnylam Pharmaceuticals、 Akari Therapeutics、 Amgen、 CSL Behring、 Bioverativ、 F. Hoffmann-La Roche Ltd、 Novartis AG、 Amgen Inc、 Teva Pharmaceutical、 Abbottなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、発作性夜間ヘモグロビン尿症（PNH）用治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：タイプ別、2018年-2023年、2024年-2029年 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：タイプ別市場シェア、2022年 ・モノクローナル抗体治療、免疫抑制剤、造血幹細胞移植 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：用途別、2018年-2023年、2024年-2029年 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：用途別市場シェア、2022年 ・病院、診療所、その他 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：地域・国別、2018年-2023年、2024年-2029年 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における発作性夜間ヘモグロビン尿症（PNH）用治療のグローバル売上、2018年-2023年 ・主要企業における発作性夜間ヘモグロビン尿症（PNH）用治療のグローバル売上シェア、2022年 ・主要企業における発作性夜間ヘモグロビン尿症（PNH）用治療のグローバル販売量、2018年-2023年 ・主要企業における発作性夜間ヘモグロビン尿症（PNH）用治療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Amoun Pharmaceuticals、 EIPICO、 Minapharm Pharmaceuticals、 Pharco Pharmaceuticals、 Alexion Pharmaceuticals、 Alnylam Pharmaceuticals、 Akari Therapeutics、 Amgen、 CSL Behring、 Bioverativ、 F. Hoffmann-La Roche Ltd、 Novartis AG、 Amgen Inc、 Teva Pharmaceutical、 Abbott ************************************************************* ・調査・分析レポートの概要 発作性夜間ヘモグロビン尿症（PNH）用治療市場の定義 市場セグメント 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場規模 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場規模：2022年 VS 2029年 世界の発作性夜間ヘモグロビン尿症（PNH）用治療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの発作性夜間ヘモグロビン尿症（PNH）用治療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の発作性夜間ヘモグロビン尿症（PNH）用治療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：モノクローナル抗体治療、免疫抑制剤、造血幹細胞移植 発作性夜間ヘモグロビン尿症（PNH）用治療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、その他 発作性夜間ヘモグロビン尿症（PNH）用治療の用途別グローバル売上・予測 ・地域別市場分析 地域別発作性夜間ヘモグロビン尿症（PNH）用治療市場規模 2022年と2029年 地域別発作性夜間ヘモグロビン尿症（PNH）用治療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Amoun Pharmaceuticals、 EIPICO、 Minapharm Pharmaceuticals、 Pharco Pharmaceuticals、 Alexion Pharmaceuticals、 Alnylam Pharmaceuticals、 Akari Therapeutics、 Amgen、 CSL Behring、 Bioverativ、 F. Hoffmann-La Roche Ltd、 Novartis AG、 Amgen Inc、 Teva Pharmaceutical、 Abbott ... |
This research report provides a comprehensive analysis of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, challenges faced by the industry, and potential opportunities for market players.
The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. Additionally, the growing consumer demand present avenues for market expansion.
The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market was valued at US$ 94 million in 2022 and is projected to reach US$ 202.1 million by 2029, at a CAGR of 11.6% during the forecast period.
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a growing area focused on developing innovative drugs and treatments to improve the quality of life of patients with PNH. The market covers various treatment options, including monoclonal antibody therapies, immunosuppressive drugs, and hematopoietic stem cell transplantation, aimed at alleviating symptoms, controlling hemolysis, and improving blood abnormalities in PNH patients, thus providing better clinical outcomes. As scientific research continues to advance and medical technology continues to improve, the PNH treatment market is expected to continue to expand, providing patients with more treatment options and the opportunity to improve survival rates.
Key Features:
The research report on the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Market Overview: The report provides a comprehensive overview of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monoclonal Antibodies Therapy, Immunosuppressive Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Monoclonal Antibodies Therapy
Immunosuppressive Drugs
Hematopoietic Stem Cell Transplantation
Market segment by Application
Hospital
Clinic
Other
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Amoun Pharmaceuticals
EIPICO
Minapharm Pharmaceuticals
Pharco Pharmaceuticals
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ
F. Hoffmann-La Roche Ltd
Novartis AG
Amgen Inc
Teva Pharmaceutical
Abbott
Outline of Major Chapters:
Chapter 1: Introduces the definition of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, market overview.
Chapter 2: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size in revenue and volume.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Overall Market Size
2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size: 2022 VS 2029
2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales: 2018-2029
3 Company Landscape
3.1 Top Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Players in Global Market
3.2 Top Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Companies Ranked by Revenue
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Companies
3.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Companies
3.5 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Type
3.8 Tier 1, Tier 2 and Tier 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Players in Global Market
3.8.1 List of Global Tier 1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Companies
3.8.2 List of Global Tier 2 and Tier 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Markets, 2022 & 2029
4.1.2 Monoclonal Antibodies Therapy
4.1.3 Immunosuppressive Drugs
4.1.4 Hematopoietic Stem Cell Transplantation
4.2 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue & Forecasts
4.2.1 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2023
4.2.2 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2024-2029
4.2.3 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share, 2018-2029
4.3 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales & Forecasts
4.3.1 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2023
4.3.2 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2024-2029
4.3.3 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share, 2018-2029
4.4 By Type – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue & Forecasts
5.2.1 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2023
5.2.2 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2024-2029
5.2.3 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share, 2018-2029
5.3 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales & Forecasts
5.3.1 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2023
5.3.2 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2024-2029
5.3.3 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share, 2018-2029
5.4 By Application – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2022 & 2029
6.2 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue & Forecasts
6.2.1 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2023
6.2.2 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2024-2029
6.2.3 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share, 2018-2029
6.3 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales & Forecasts
6.3.1 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2023
6.3.2 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2024-2029
6.3.3 By Region – Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2029
6.4.2 By Country – North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2029
6.4.3 US Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.4.4 Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.4.5 Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2029
6.5.2 By Country – Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2029
6.5.3 Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5.4 France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5.5 U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5.6 Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5.7 Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5.8 Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.5.9 Benelux Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2029
6.6.2 By Region – Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2029
6.6.3 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.6.4 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.6.5 South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.6.6 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.6.7 India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2029
6.7.2 By Country – South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2029
6.7.3 Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.7.4 Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, 2018-2029
6.8.3 Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.8.4 Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.8.5 Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
6.8.6 UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amoun Pharmaceuticals
7.1.1 Amoun Pharmaceuticals Company Summary
7.1.2 Amoun Pharmaceuticals Business Overview
7.1.3 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.1.4 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.1.5 Amoun Pharmaceuticals Key News & Latest Developments
7.2 EIPICO
7.2.1 EIPICO Company Summary
7.2.2 EIPICO Business Overview
7.2.3 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.2.4 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.2.5 EIPICO Key News & Latest Developments
7.3 Minapharm Pharmaceuticals
7.3.1 Minapharm Pharmaceuticals Company Summary
7.3.2 Minapharm Pharmaceuticals Business Overview
7.3.3 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.3.4 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.3.5 Minapharm Pharmaceuticals Key News & Latest Developments
7.4 Pharco Pharmaceuticals
7.4.1 Pharco Pharmaceuticals Company Summary
7.4.2 Pharco Pharmaceuticals Business Overview
7.4.3 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.4.4 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.4.5 Pharco Pharmaceuticals Key News & Latest Developments
7.5 Alexion Pharmaceuticals
7.5.1 Alexion Pharmaceuticals Company Summary
7.5.2 Alexion Pharmaceuticals Business Overview
7.5.3 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.5.4 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.5.5 Alexion Pharmaceuticals Key News & Latest Developments
7.6 Alnylam Pharmaceuticals
7.6.1 Alnylam Pharmaceuticals Company Summary
7.6.2 Alnylam Pharmaceuticals Business Overview
7.6.3 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.6.4 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.6.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.7 Akari Therapeutics
7.7.1 Akari Therapeutics Company Summary
7.7.2 Akari Therapeutics Business Overview
7.7.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.7.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.7.5 Akari Therapeutics Key News & Latest Developments
7.8 Amgen
7.8.1 Amgen Company Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.8.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.8.5 Amgen Key News & Latest Developments
7.9 CSL Behring
7.9.1 CSL Behring Company Summary
7.9.2 CSL Behring Business Overview
7.9.3 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.9.4 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.9.5 CSL Behring Key News & Latest Developments
7.10 Bioverativ
7.10.1 Bioverativ Company Summary
7.10.2 Bioverativ Business Overview
7.10.3 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.10.4 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.10.5 Bioverativ Key News & Latest Developments
7.11 F. Hoffmann-La Roche Ltd
7.11.1 F. Hoffmann-La Roche Ltd Company Summary
7.11.2 F. Hoffmann-La Roche Ltd Business Overview
7.11.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.11.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.11.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.12 Novartis AG
7.12.1 Novartis AG Company Summary
7.12.2 Novartis AG Business Overview
7.12.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.12.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.12.5 Novartis AG Key News & Latest Developments
7.13 Amgen Inc
7.13.1 Amgen Inc Company Summary
7.13.2 Amgen Inc Business Overview
7.13.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.13.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.13.5 Amgen Inc Key News & Latest Developments
7.14 Teva Pharmaceutical
7.14.1 Teva Pharmaceutical Company Summary
7.14.2 Teva Pharmaceutical Business Overview
7.14.3 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.14.4 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.14.5 Teva Pharmaceutical Key News & Latest Developments
7.15 Abbott
7.15.1 Abbott Company Summary
7.15.2 Abbott Business Overview
7.15.3 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Major Product Offerings
7.15.4 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Revenue in Global (2018-2023)
7.15.5 Abbott Key News & Latest Developments
8 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Production Capacity, Analysis
8.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Production Capacity, 2018-2029
8.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Production Capacity of Key Manufacturers in Global Market
8.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Supply Chain Analysis
10.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry Value Chain
10.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Upstream Market
10.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer